Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Results of Operations and Financial Condition

Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Results of Operations and Financial Condition
Item 2.02.

Story continues below

Results of Operations and Financial Condition

On February13, 2019, Natus Medical Incorporated (the “Company”) is issuing a press release and holding a conference call regarding its financial results for the fourth quarter ended December31, 2018 and other financial information. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 2.02.

Financial Statements and Exhibits

(d) Exhibits.

ExhibitNo.

Description

99.1

Press release dated February 13, 2019 describing the Company’s results for its fourth quarter ended December 31, 2018 and other financial information.

NATUS MEDICAL INC Exhibit
EX-99.1 2 a2018-q4earningsrelease.htm EXHIBIT 99.1 Exhibit Natus Medical Announces Fourth Quarter and Full Year 2018 Financial Results•Reports record fourth quarter revenue of $141.0 million•Reports fourth quarter GAAP loss per share of $0.35 and non-GAAP earnings per share of $0.43•Provides annual revenue and earnings guidance for 2019PLEASANTON,…
To view the full exhibit click here

About Natus Medical Incorporated (NASDAQ:BABY)

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care.

An ad to help with our costs